Novartis, Anthos

Novartis buys Blackstone's Anthos for up to $3.1 billion
By Ludwig Burger and Ariane Luthi (Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.
Novartis acquires local cardiovascular drugmaker Anthos for $925 million
Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots.
Novartis buys back Anthos Therapeutics for up to $3.1B
Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement of regulatory and sales milestones. The transaction, which could reach $3.1 billion in total value, is expected to close in the early part of 2025.
Novartis agrees to acquire Anthos for up to $3.1 billion
Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, the companies said on Tuesday.
M&A News: Novartis Seals $3.1B Deal to Acquire Anthos
Novartis (NVS) has sealed a $3.1 billion deal to acquire clinical-stage biopharmaceutical company Anthos Therapeutics. The deal includes an
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 billion
Novartis Strikes Deal to Acquire Anthos Therapeutics
Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients with atrial fibrillation and cancer-associated thrombosis.
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the activated form (Factor XIa). This mimics natural Factor XI deficiency, which is associated with protection from thromboembolic disease.
Novartis to buy Anthos Therapeutics for $925 million
Novartis AG agreed to buy US biotech Anthos Therapeutics for as much as $3.1 billion to gain a preventative stroke medicine that could be the first of its kind. The Swiss drugmaker will pay $925 million upfront and as much as $2.
BioPharma Dive3d
Novartis pays $925M to reel in a startup it helped launch
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...
Novartis to pay $3.1B for Cambridge biotech led by former Karuna CEO
In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now ...
Is Novartis AG (NVS) the Best Foreign Dividend Stock to Buy According to Analysts?
We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...